Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE (Vamorolone) in countries where the product is not otherwise commercially available.
Travel mania Shutterstock
Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.
“This distribution agreement with Clinigen, which is complementary to other, earlier announced, partnerships and agreements, will allow Santhera to significantly increase our service level to patients and healthcare professionals through processing individual requests for AGAMREE from geographies in which Santhera is not directly represented or while negotiations with local partners are ongoing,” said Geert Jan van Daal, MD, PhD, chief commercial officer of Santhera.
“DMD is one of the most common and devastating types of muscular degeneration, it is a progressive condition diagnosed in childhood and it is encouraging to be able to help healthcare professionals support appropriate patients with an additional treatment option. We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. This partnership demonstrates our ongoing commitment to accelerate access to medicines, to improve the quality of people’s lives around the world,” said Julie Gosper, senior vice president, Europe and Partner Markets at Clinigen.
In addition to opening this distribution channel, Santhera continues its gradual rollout of AGAMREE in key European geographies. Commercialisation of AGAMREE in Germany and Austria, where the reception has been very positive, started in Q1-2024. Santhera plans to launch AGAMREE in Europe's other major markets, with the UK (including Scotland) in early 2025. The rollout will continue throughout 2025 across France, Italy, Spain, and other European countries. Santhera continues to expand its partner network, which already includes multiple geographies, to bring AGAMREE to patients with DMD in need of treatment.